- Home
- BLRX vs MNDO Comparison
BLRX vs MNDO Comparison
Compare BLRX & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- MNDO
- Stock Information
- Founded
- BLRX 2003
- MNDO 1995
- Country
- BLRX Israel
- MNDO Israel
- Employees
- BLRX N/A
- MNDO N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- MNDO EDP Services
- Sector
- BLRX Health Care
- MNDO Technology
- Exchange
- BLRX Nasdaq
- MNDO Nasdaq
- Market Cap
- BLRX 36.0M
- MNDO 39.8M
- IPO Year
- BLRX 2011
- MNDO 2000
- Fundamental
- Price
- BLRX $0.48
- MNDO $1.98
- Analyst Decision
- BLRX Strong Buy
- MNDO
- Analyst Count
- BLRX 2
- MNDO 0
- Target Price
- BLRX $11.50
- MNDO N/A
- AVG Volume (30 Days)
- BLRX 407.5K
- MNDO 24.5K
- Earning Date
- BLRX 11-29-2024
- MNDO 11-05-2024
- Dividend Yield
- BLRX N/A
- MNDO 12.15%
- EPS Growth
- BLRX N/A
- MNDO N/A
- EPS
- BLRX N/A
- MNDO 0.23
- Revenue
- BLRX $17,048,000.00
- MNDO $21,856,000.00
- Revenue This Year
- BLRX N/A
- MNDO N/A
- Revenue Next Year
- BLRX N/A
- MNDO N/A
- P/E Ratio
- BLRX N/A
- MNDO $8.59
- Revenue Growth
- BLRX N/A
- MNDO 2.27
- 52 Week Low
- BLRX $0.39
- MNDO $1.70
- 52 Week High
- BLRX $1.93
- MNDO $2.28
- Technical
- Relative Strength Index (RSI)
- BLRX 53.32
- MNDO 52.34
- Support Level
- BLRX $0.40
- MNDO $1.90
- Resistance Level
- BLRX $0.46
- MNDO $2.00
- Average True Range (ATR)
- BLRX 0.03
- MNDO 0.03
- MACD
- BLRX 0.01
- MNDO -0.00
- Stochastic Oscillator
- BLRX 94.50
- MNDO 75.00
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets and implements real-time and off-line convergent billing and customer care software solutions. The company derives revenue from sale of software products and services in two operating segments namely Billing and Related Services, which derives key revenue and Messaging. The Company has three product lines: Product line A- billing and customer care solutions for service providers; Product line B - call accounting and call management solutions for enterprises; and Product line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in The Americas, Europe, Asia Pacific and Africa and Israel. It earns maximum revenue from Europe.